Bulent Ozpolat
Associate Professor
The University of Texas MD Anderson Cancer Center
USA
Biography
Dr. Bulent Ozpolat is an associate professor in Department of Experimental Therapeutics, Division of Cancer Medicine, UTMDACC, Houston, TX. Dr. Ozpolat is a member of Center for Targeted Therapy, Alliance for Nano heath, Texas Center Cancer Nanomedicine (CCNE), Ovarian Cancer Moonshots, Non-Coding RNA Center at MDACC and closely collaborating Dr. Kevin Dalby (UT-Austin) Dr. Michael Ittmann, (Baylor College of Medicine), Dr. James Sahn (UT-Austin), Jonathan Sessler (UT-Austin) Dr. Fahri Saatcioglu (University of Oslo). As part of ovarian cancer study group Dr. Ozpolat is collaborating with Drs. Lopez-Berestein, Sood and Coleman to develop tumor- targeted therapies. He serves as a reviewer for several journals and study sections and published many papers and review articles in high impact journals and contributed to 12 book chapters. Dr. Ozpolat is holding a patent and several applications are pending.
Research Interest
Developing highly specific tumor-targeting nanocarriers (nanoliposomes and polymer-based nanoparticles) for the delivery of oligonucleotides, non-coding RNAs (i.e., siRNA, microRNA , anti-Mirs), peptides, proteins, drugs and small molecule inhibitors, Studying the role of survival pathways, including autophagy and eEF2-kinase (eEF2K) signaling and development of novel therapeutic agents (small molecule inhibitors and siRNA-based nanotherapeutics) that target these pathways and Development of these agents into clinical strategies for patients.